Roles and mechanisms of aberrant alternative splicing in melanoma - implications for targeted therapy and

Related Experiment Video

Updated: Jul 1, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.0K

Wanxian Chen1,2, Deyi Geng1,2, Jiasheng Chen1,2

  • 1Department of Plastic and Burns Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, 515000, P. R. China.

Cancer Cell International
|March 11, 2024
PubMed
Abstract

Insights

Alternative splicing impacts melanoma development and treatment resistance. Understanding these changes offers new diagnostic biomarkers and therapeutic strategies for melanoma patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cancer Research

Background:

  • Melanoma treatment faces challenges due to immunotherapy resistance and targeted therapy side effects.
  • Alternative splicing is a key process in melanoma development and progression.

Purpose of the Study:

  • To review the role of alternative splicing in melanoma.
  • To explore how alternative splicing affects melanoma metastasis and treatment efficacy.
  • To identify potential diagnostic biomarkers and therapeutic targets related to splicing.

Main Methods:

  • Comprehensive literature review on alternative splicing in melanoma.
  • Analysis of the impact of aberrant splicing on gene expression and cellular processes.
  • Integration of findings on splicing factors and variants in melanoma pathogenesis.

Main Results:

  • Aberrant alternative splicing is implicated in melanoma development, metastasis, and resistance to therapies.
  • Abnormal expression of splicing factors and variants can serve as prognostic and diagnostic indicators.
  • Splicing alterations represent potential targets for novel melanoma treatments.

Conclusions:

  • Developing novel diagnostic biomarkers based on splicing alterations is crucial for melanoma.
  • Targeting alternative splicing mechanisms may overcome resistance to targeted therapies and immunotherapy.
  • A deeper understanding of splicing in melanoma can lead to improved patient outcomes.
Keywords:
Alternative splicingDiagnostic biomarkersImmunotherapyMelanomaTargeted therapy

More Related Videos

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

12.9K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.7K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.3K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Chromatin Structure Regulates pre-mRNA Processing02:41

Chromatin Structure Regulates pre-mRNA Processing

In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
What is Gene Expression?01:36

What is Gene Expression?

A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is comprised  of nucleotides and proteins are comprised of amino acids, a mediator is required to convert the information encoded in DNA into proteins. This mediator is the messenger RNA (mRNA). mRNA copies the blueprint from DNA by a process called transcription. In eukaryotes, transcription occurs in the nucleus by complementary base-pairing with the DNA template. The mRNA is then...
8.5K